Skip to main content
NAMSW logo

NAMSW · NewAmsterdam Pharma Co N.V. · Debt

Track NAMSW — free
$10.40 Q3 2025 earnings call transcript
Market Cap
$2.45B
Shares
119.54M
Volume · Oct 26 241 Avg daily vol (3M) 2621

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2026-06-30 USD 26,000 10-Q filed 2026-08-05
Noncurrent operating lease liabilities 2026-06-30 USD 56,000 10-Q filed 2026-08-05
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1936258 CUSIP N62509109 Visit website Investor relations